Back to search

National and Kapodistrian University of Athens

Η επίδραση των ανταγωνιστών της αγγειοτασίνης-ΙΙ στη λειτουργικότητα του ενδοθηλίου σακχαροδιαβητικών ασθενών

Abstract

dc:description

A)Aim: To test the impact of telmisartan (an angiotensin receptor blocker: ARB) on ultrasound and biochemical parameters of the vascular endothelium and the diastolic properties of the left ventricle (LV) in normotensive patients with type 2 diabetes. Telmisartan’s effect was assessed in comparison with the analogue effect of ramipril (an ACE-inhibitor: ACE-I), as well as their combination on the same parameters of the aforesaid patients.B)Methods: Fourty-four patients were recruited in this prospective, randomized, double-blind, cross-over trial. Exclusion criteria included a history of hypertension, coronary or peripheral artery disease, severe valvulopathy, pulmonary hypertension, left ventricular (LV) hypertrophy, heart or renal failure and poorly controlled diabetes (glycated hemoglobin >7.5%). Furthermore, patients should abstain from drugs with a potential confounding effect on the endothelial function (i.e. ACE-inhibitors, ARBs, statins, folic acid) throughout the study and 6 months prior to it.All patients randomly received one of the following therapeutic regimens for a period of 3 months: a) ramipril 2.5mg/daily plus placebo, b) telmisartan 40mg/daily plus placebo, c) combination treatment of ramipril 2.5mg and telmisartan 40mg daily. Following the completion of the therapeutic trimester, a 2-week wash-out period intervened and subsequently all patients were randomly crossed-over to one of the 2 remaining alternative regimens. Finally, after 2 more weeks for wash-out they were put on the last regimen. A detailed medical history was obtained and a thorough physical examination and an electrocardiogram were done at baseline. In the beginning of the study and at the end of every therapeutic trimester (i.e. 0, 3, 6, 9 months) the brachial artery Flow-Mediated Dilation (FMD) and the echocardiographic LV diastolic indices were assessed. At the same time, blood draws for inflammatory, oxidative, fibrinolytic-coagulation markers, adipokines and other biochemical factors were obtained. C)Results: Both ramipril and telmisartan improved the endothelial function (increased the FMD) and the diastolic indices of the LV, with the former drug being more effective than the latter. Both drugs had a favorable impact on the inflammatory burden and the level of oxidative stress. From paired statistical analysis, it was shown that telmisartan increased the serum levels of the cardio-protective adiponectin, whereas ramipril did not. Furthermore, telmisartan, as compared to ramipril, caused greater decline in the serum levels of BNP. On the contrary, the reversal of the fibrinolytic-coagulation imbalance was better with ramipril than telmisartan, mainly due to the increase of serum t-PA levels. Combination treatment increased the serum levels of adiponectin and caused greater reduction in plasma BNP levels, as compared to ramipril alone. On the other hand, the anti-oxidant properties and the restoration of the fibrinolytic-coagulation balance were better when combining ramipril with telmisartan than with monotherapy with telmisartan. Combination treatment resulted in greater increase of the FMD and improvement of the echocardiographic diastolic indices of LV. The prevalence of LV diastolic dysfunction in these asymptomatic normotensive diabetic patients, which by many researchers is considered to be the first stage of the diabetic cardiomyopathy, declined to 36% with combination therapy as compared to 67% at baseline and 50% and 43% with ramipril and telmisartan respectively. D) Conclusions: Both ramipril and telmisartan have salutary effects on the vascular endothelial function and the diastolic properties of the LV in diabetic patients, whereas combination therapy yields better results than either drug alone. This is accomplished through their potent pleiotropic and particularly anti-inflammatory and anti-oxidant properties, as they were recorded in our study. The different mechanisms of action between telmisartan and ramipril that were shown in our study probaply account for telmisartan’s superiority over ramipril.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2010

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Simeonidis, Phevos
  • Συμεωνίδης, Φοίβος

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40003

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Simeonidis, Phevos; Συμεωνίδης, Φοίβος. Η επίδραση των ανταγωνιστών της αγγειοτασίνης-ΙΙ στη λειτουργικότητα του ενδοθηλίου σακχαροδιαβητικών ασθενών. National and Kapodistrian University of Athens, 2010. http://hdl.handle.net/10442/hedi/40003